1. Body composition is associated with poor overall survival and accelerated time to progression in HCC patients treated with sorafenib. (September 2018) Authors: Labeur, T.; van Vugt, J.; ten Cate, D.; Takkenberg, B.; Groot Koerkamp, B.; de Man, R.; van Delden, O.; IJzermans, J.; Eskens, F.; Klumpen, H.-J. Journal: HPB Issue: Volume 20(2018)Supplement 2 Page Start: S263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗